Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -72.00 | -96.65 | -74.05 | -33.66 | -- |
| EBIT | -15.55 | 29.23 | 53.43 | 14.11 | -6.19 |
| Net Profit | -16.16 | 36.69 | 69.05 | 13.88 | -7.07 |
| EPS | 86.78 | -165.37 | -559.95 | -232.63 | -223.85 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-25 | Dec-24 | Dec-23 |
| EBIT-Margin
| -5,196.80 | -6,985.68 | -7,425.38 | -3,959.13 | -4,205.91 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -2,284.55 | -1,405.53 | -6,594.98 | -184.99 | -73.67 |
| Return on Capital
| -88.58 | -86.52 | -88.28 | -115.16 | -62.30 |
| Return on Assets
| -65.17 | -65.02 | -56.45 | -89.43 | -49.63 |
| Debt to Equity (x)
| -- | -- | -2.82 | 2.97 | 0.30 |
Profitability
ROCE
-88.28
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-88.28
|
-115.16
|
-62.30
|
-91.60
|
-75.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-6,594.98
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-6,594.98
|
-184.99
|
-73.67
|
-96.08
|
-77.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-56.45
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-56.45
|
-89.43
|
-49.63
|
-67.07
|
-62.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-7,425.38
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-7,425.38
|
-3,959.13
|
-4,205.91
|
-4,034.48
|
-15,303.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-7,266.08
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-7,266.08
|
-6,090.94
|
-4,023.11
|
-4,055.61
|
-14,880.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-0.74
--
Year on year growth in net sales
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-0.74
|
-0.02
|
0.14
|
3.78
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
51.34
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
51.34
|
7.32
|
-19.16
|
-26.08
|
-96.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
69.05
--
Year on year growth in profit after tax
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
69.05
|
-49.07
|
-13.39
|
-30.34
|
-91.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-0.30
--
Year on year growth in earnings per share
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-0.30
|
-0.41
|
0.41
|
0.47
|
-0.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-2.82
--
Total debt / Net worth
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-2.82
|
2.97
|
0.30
|
0.05
|
0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.45
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-0.45
|
0.36
|
0.06
|
0.04
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.71
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
1.71
|
3.41
|
5.35
|
6.97
|
2.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
--
|
--
|
--
|
-104.94
|
-427.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
--
Sales / Average Total Assets
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
0.01
|
0.01
|
0.01
|
0.02
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
--
|
1,671.15
|
21.85
|
982.61
|
738.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-1.65
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-1.65
|
-0.14
|
-5.14
|
-1.81
|
-1.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
-4.46
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-4.46
|
1.16
|
3.61
|
1.24
|
1.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.14
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
-2.14
|
-0.12
|
-3.78
|
-0.12
|
-0.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|